Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists
Koc-Kan Ho1, Douglas S Auld, Adolph C Bohnstedt
1Pharmacopeia Drug Discovery, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA. kanho@pcop.com
Abstract:
An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Inhibition of Cdk Activity
Antiviral Nucleoside Inhibitors
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
